Jeff Aronin

Last updated
Jeff Aronin
Born (1967-12-08) December 8, 1967 (age 56)
EducationBA (Marketing) 1989 [1]
Alma mater Northern Illinois University [1]
Occupation(s)Chairman and CEO of Paragon Biosciences, LLC

Jeff Aronin (born December 8, 1967) is an American investor, entrepreneur, and biotechnology executive. He is founder, chairman and CEO of Paragon Biosciences, LLC, a global life science company that creates, builds, and funds innovative biology-based companies. [2]

Contents

Early life and education

Aronin discovered his passion for pharmaceutical development while shadowing a physician who was treating an epileptic pediatric patient with regular seizures. Confronted with limited options to stop the seizures other than to remove a portion of the young patient's brain, the doctor pursued an alternative treatment with a dosage of medication that successfully curbed the child's seizures, preventing the life-altering surgery and setting Aronin on his course to become an entrepreneur in the biopharmaceutical industry. [3]

Aronin holds an M.B.A. from DePaul University and earned a B.S. from Northern Illinois University. He also lectures on entrepreneurship at the University of Chicago Booth School of Business and Northwestern University's Kellogg School of Management, where he completed post-graduate coursework. In 2010, he was named an Aspen Institute Henry Crown Fellow. [4]

Career

Aronin is the chairman of multiple Paragon portfolio companies including Harmony Biosciences (HRMY), Evozyne, Castle Creek Biosciences, Emalex Biosciences, and CiRC Biosciences, and previously Marathon Pharmaceuticals, a research based prescription biopharmaceutical company. [5] [6] [7] Prior to Paragon, Aronin founded Ovation Pharmaceuticals LLC in 2000 and served as its chairman and CEO for nine years. On February 9, 2009, it was announced that H. Lundbeck A/S, a Danish pharmaceutical company, had purchased Ovation for $900 million. [8] Chicago Mayor Rahm Emanuel appointed Aronin to the board of directors of World Business Chicago [9] and co-chair of ChicagoNEXT. [10] Aronin is also a former chair of MATTER, a start-up center in Chicago for next-generation healthcare technology companies that opened in February 2015. [11] [12] He also serves on the board of trustees of Discover Financial Services. [13] He previously served on the board of trustees of the Museum of Science and Industry. [14]

In 2022 Aronin won a Gold Stevie Award and was named Entrepreneur of the Year – Pharmaceuticals. [15] He also received a Titan Award for biology-based innovation. [16]

Philanthropy

Chicago Mayor Rahm Emanuel appointed Aronin to the board of directors of World Business Chicago (WBC), public-private partnership between the city and Chicago's business community to spur economic and job growth, and co-chair of ChicagoNEXT, WBC's council of technology leaders dedicated to driving opportunity in innovation and entrepreneurship in the region. [17] Aronin is also chair of ChicagoNEXT's bioscience committee, where he spearheaded development of the health technology startup center MATTER. He also serves on the board of trustees of Discover Financial Services [18] and previously served on the board of trustees of Chicago's Museum of Science and Industry. [18] Aronin and his wife Lisa, thru the Aronin Family Foundation, support patient advocacy and research at organizations such as the American Porphyria Foundation, Huntington's Disease Society of America and the Pediatric Epilepsy Research Foundation. In November 2017 the Weizmann Institute of Science awarded Aronin the Weizmann Leadership Award. [19] [20]

MATTER

Aronin is founder and former chairman of MATTER, an incubator community of healthcare innovators dedicated to improving patients' lives and solving complex problems confronting the healthcare industry launched in 2014. MATTER has supported more than 1,000 companies that have raised more than $5 billion to fuel their growth. [21] Aronin was recognized in 2015 by the Chicagoland Entrepreneurial Center (CEC) for his leadership and contributions to establishing MATTER, awarding Aronin its Entrepreneurial Champion Award. [3]

Related Research Articles

<span class="mw-page-title-main">Merck Group</span> German multinational science and technology company

The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally.

<span class="mw-page-title-main">Brook Byers</span>

Brook Byers is a senior partner at Kleiner Perkins Caufield & Byers and the brother of Stanford University Professor Tom Byers and Atlanta, Georgia engineering entrepreneur Ken Byers.

Ovation Pharmaceuticals is an American manufacturer and distributor of pharmaceuticals products. It was founded in 2000 by Jeffrey Aronin and is headquartered in Deerfield, Illinois. A major office is also located near Lebanon, New Jersey. Ovation is a privately held corporation based on a business model of acquiring mature but under-promoted pharmaceuticals, as well as pharmaceutical candidates which are far along the development and FDA certification processes. Since 2009, the company has been wholly owned by the Danish pharmaceutical company Lundbeck.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

<span class="mw-page-title-main">Robert S. Langer</span> American scientist

Robert Samuel Langer Jr. FREng is an American biotechnologist, businessman, chemical engineer, chemist, and inventor. He is one of the nine Institute Professors at the Massachusetts Institute of Technology.

<span class="mw-page-title-main">Kiran Mazumdar-Shaw</span> Indian entrepreneur (Biocon), billionaire

Kiran Mazumdar-Shaw is an Indian billionaire entrepreneur. She is the executive chairperson and founder of Biocon Limited and Biocon Biologics Limited, a biotechnology company based in Bangalore, India and the former chairperson of Indian Institute of Management, Bangalore. In 2014, she was awarded the Othmer Gold Medal for outstanding contributions to the progress of science and chemistry. She was on the Financial Times 2011 top 50 women in business list. In 2019, she was listed as the 68th most powerful woman in the world by Forbes. She was named EY World Entrepreneur Of The Year 2020. She was married to John Shaw.

Fred Hassan, is a Pakistan-born American business executive who works for Warburg Pincus and was CEO of three global pharmaceutical companies.

<span class="mw-page-title-main">Joe Kiani</span> Iranian-born American entrepreneur (born 1964)

Massi Kiani, known as Joe Kiani, is an Iranian-born American engineer, entrepreneur, and corporate executive. He is the founder of medical technology company Masimo, which was initially established in 1989. In 2021, he was appointed by President Joe Biden to serve on the President's Council of Advisors on Science and Technology (PCAST).

Gregory David Wasson is an American businessman. He is the co-founder and president of Wasson Enterprise, a family-based investment office, the executive chairman of Innventure, co-founder of CoolerScreens, and the former president and chief executive officer (CEO) of Walgreens Boots Alliance (NASDAQ:WBA).

Duane J. Roth was chief executive officer and member of the board of CONNECT. He graduated from Iowa Wesleyan College.

Mark Tebbe is an Adjunct Professor of Entrepreneurship at the University of Chicago's Booth School of Business where he helped develop and co-teaches the Entrepreneurial Discovery class having served in this role since 2011. In addition to his appointment as Adjunct Professor, Mark is an Entrepreneur-in-Residence in Booth's Polsky Center for Entrepreneurship and Innovation where he mentors students and advises faculty in developing technological business techniques. He is an active investor and mentor to various companies in the startup ecosystem as part of Hyde Park Angels.

Richard William Barker is the Founder of New Medicine Partners and Founding Director of the University of Oxford — University College of London Centre for the Advancement of Sustainable Medical Innovation (CASMI).

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

Ann Jacqueline Hunter CBE FMedSci FBPharmacolS FRSB is a British scientist who is a board director of BenevolentAI. Hunter is also a visiting professor at St George's Hospital Medical School and Imperial College. She is Chair of the Trustees of the Sainsbury Laboratories at Norwich, chair of the board of the Stevenage Bioscience Catalyst and chair of the board of Brainomix. She was previously CEO of the Biotechnology and Biological Sciences Research Council.

<span class="mw-page-title-main">Jeroen Tas</span> Dutch entrepreneur

Jeroen Tas is a Dutch entrepreneur and senior executive in the healthcare, information technology and financial services industries. In February 2017, he assumed the role as Chief Innovation & Strategy Officer at Philips Healthcare, a position he held until July 2021. He currently works on Strategic Business Development and is also a member of the executive committee at Royal Philips.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

The Biotechnology Innovation Organization (BIO) is the largest advocacy association in the world representing the biotechnology industry. It was founded in 1993 as the Biotechnology Industry Organization from a merger of the Industrial Biotechnology Association (IBA) and the Association of Biotechnology Companies (ABC), and changed its name to the Biotechnology Innovation Organization on January 4, 2016. Biotechnology Innovation Organization serves more than 1,100 biotechnology firms, research schools, state biotechnology centers and related associations in the United States and in more than 30 other countries.

<span class="mw-page-title-main">Joshua Boger</span> Organic chemist and the founder of Vertex Pharmaceuticals

Joshua S. Boger is an organic chemist and the founder of Vertex Pharmaceuticals Incorporated. He is considered a pioneer in the field of structure-based rational drug design. Drugs developed include amprenavir, an HIV protease inhibitor; telaprevir, a protease inhibitor for treatment of hepatitis C; and Kalydeco, for the treatment of cystic fibrosis. In 2003, Vertex was listed as one of forty worldwide Technology Pioneers by the World Economic Forum. As of 2012, Boger became executive chairman of Alkeus Pharmaceuticals.

<span class="mw-page-title-main">Jeffrey Leiden</span> CEO of biotechnology company

Jeffrey Leiden is an American businessman who is the executive chairman of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts. He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020.

<span class="mw-page-title-main">William Rastetter</span> American scientist, entrepreneur and venture capitalist

William H.Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He is a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics and Entos, Inc.. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.

References

  1. 1 2 Colleen Leonard, The Man Behind Global Pharmas
  2. ↑ Kapos, Shia (9 March 2010). "Jeff Aronin back in business with new pharma company". Crain's Chicago Business. Retrieved 14 July 2014.
  3. 1 2 "Tales from the Trenches: Jeff Aronin". Matter. 17 January 2017.
  4. ↑ "Aspen Institute Names Emerging Leaders as 2010 Henry Crown Fellows". The Aspen Institute. Retrieved 2020-04-22.
  5. ↑ "Harmony Biosciences lands $270M equity financing, U.S. License for narcolepsy drug". Bioworld. October 9, 2019.
  6. ↑ "Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America". October 27, 2017.
  7. ↑ "Castle Creek Pharmaceuticals Announces Hiring Dr. Amir Tavakkol Executive Vice President Chief Development Officer". PR Newswire. October 9, 2019.
  8. ↑ Graham, Meg. "Jeff Aronin of Marathon Pharmaceuticals on life after a $900M exit". Chicagotribune.com. The Chicago Tribune. Retrieved 3 December 2015.
  9. ↑ "Board of Directors". World Business Chicago. Retrieved 14 July 2014.
  10. ↑ "Leadership". World Business Chicago. Retrieved 14 July 2014.
  11. ↑ Pletz, John (11 February 2014). "The formation of Matter, Chicago's new health-tech incubator". Crain's Chicago Business. Retrieved 14 July 2014.
  12. ↑ "Governor Quinn Announces MATTER, a New Healthcare Technology Startup Hub". MATTER. Retrieved 14 July 2014.
  13. ↑ "Board of Directors". Discover. Retrieved 14 July 2014.
  14. ↑ "Museum of Science and Industry Leadership". Museum of Science and Industry. Archived from the original on 16 April 2009. Retrieved 14 July 2014.
  15. ↑ "Stevie Awards - Entrepreneur Awards". The American Business Awards. 2022.
  16. ↑ "Biology-based Innovation to Help People and the World". Titan Awards. 2022.
  17. ↑ "Governor Quinn, Mayor Emanuel and MATTER Founders Announce Health Innovation Technology Hub Buildout and Opening of Membership Applications". City of Chicago. August 2014.
  18. 1 2 "Jeff Aronin Named Entrepreneurial Champion by Chicagoland Entrepreneurial Center for 2015 Momentum Awards - 1871 Chicago". 1871.com. Archived from the original on 2017-09-30.
  19. ↑ "2017 Midwest Gala Dinner - Honoring Jeffrey Aronin | Weizmann USA". 25 October 2017.
  20. ↑ "Weizmann Institute - Midwest Region | Jeffrey S. Aronin Tribute". 13 November 2017.
  21. ↑ "MATTER Investor Community".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.